Boehringer Ingelheim Company Profile

What is the competitive landscape for BOEHRINGER INGELHEIM

BOEHRINGER INGELHEIM has fifty approved drugs.

There are seventy-three US patents protecting BOEHRINGER INGELHEIM drugs.

There are one thousand nine hundred and two patent family members on BOEHRINGER INGELHEIM drugs in sixty-five countries and two hundred and thirty-two supplementary protection certificates in nineteen countries.

Summary for Boehringer Ingelheim

International Patents:	1902
US Patents:	73
Tradenames:	39
Ingredients:	31
NDAs:	50
Patent Litigation for Boehringer Ingelheim:	See patent lawsuits for Boehringer Ingelheim
PTAB Cases with Boehringer Ingelheim as petitioner:	See PTAB cases with Boehringer Ingelheim as petitioner

Drugs and US Patents for Boehringer Ingelheim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-004	Dec 9, 2016		RX	Yes	Yes	10,596,120*PED				Y
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-001	Jan 30, 2012	AB	RX	Yes	No	10,973,827*PED				Y
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-005	Feb 19, 2010		DISCN	Yes	No	7,695,734		Y
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-003	Jan 30, 2012	AB	RX	Yes	Yes	8,673,927*PED				Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-004	Dec 9, 2016		RX	Yes	Yes	7,713,938*PED				Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No	7,579,449*PED				Y

Expired US Patents for Boehringer Ingelheim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	6,176,242
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015	7,056,916
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015	8,044,046
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011	5,497,944
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-001	Jul 1, 1997	6,194,445
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-002	Dec 30, 1985	4,031,244

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	2.25 mg and 3.75 mg		2011-07-26
	Extended-release Tablets	400 mg		2013-06-21
	Tablets	10 mg/5 mg and 25 mg/5 mg		2018-08-01
	Tablets	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg		2015-05-04
	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg		2008-12-31
	Extended-release Capsules	25 mg and 200 mg		2007-02-01
	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg		2005-06-24
	Capsules	eq. to 75 mg base and 150 mg base		2014-10-20
	Tablets	0.75 mg		2008-07-31
	Inhalation Powder Capsules	18 mcg		2018-05-11
	Tablets	5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg		2018-08-01
	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg		2010-06-01
	Extended-release Tablets	5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg		2018-08-01
	Tablets	20 mg, 30 mg and 40 mg		2017-07-12
	Tablets	10 mg and 25 mg		2018-08-01
	Tablets	20 mg, 40 mg and 80 mg		2006-12-26
	Tablets	80 mg/25 mg		2009-02-27
	Capsules	100 mg and 150 mg		2018-10-15
	Tablets	0.25 mg		2005-05-27
	Capsules	eq. to 110 mg base		2015-12-15
	Oral Suspension	7.5 mg/5 mL		2009-12-17
	Extended-releaseTablets	2.5 mg/1000 mg 5 mg/1000 mg		2018-03-28
	Tablets	5 mg		2015-05-04

International Patents for Boehringer Ingelheim Drugs

Country	Patent Number	Estimated Expiration
Mexico	2010013092
Denmark	2525812
Mexico	2010001696
Denmark	2482806
Japan	2014058581
Portugal	1706210

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2187879	17C1016	France		PRODUCT NAME: COMBINAISON D'EMPAGLIFLOZINE ET DE LINAGLIPTINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/16/1146 20161115
1730131	CA 2014 00054	Denmark		PRODUCT NAME: EMPAGLIFLOZIN OG SALTE DERAF, SAERLIGT EMPAGLIFLOZIN; REG. NO/DATE: EU1/14/930/001/018 20140522
1562603	122014000018	Germany		PRODUCT NAME: OLODATEROL, OPTISCHE ISOMERE DAVON, MISCHUNGEN VON ISOMEREN DAVON, SAEUREADDITIONSSALZE DAVON MIT PHARMAKOLOGISCH UNBEDENKLICHEN SAEUREN, SOWIE SOLVATE UND/ODER HYDRATE DAVON, INSBESONDERE OLODATEROL UND OLODATEROLHYDROCHLORID; NAT. REGISTRATION NO/DATE: 87146.00.00 20131126; FIRST REGISTRATION: MALTA MA 211/00401 20130918
2525812	2017/030	Ireland		PRODUCT NAME: IDARUCIZUMAB; REGISTRATION NO/DATE: EU/15/1056/001 20151120
1971601	C20210018 00331	Estonia		PRODUCT NAME: TUKATINIIB;REG NO/DATE: EU/1/20/1526 12.02.2021
1084705	PA2014044	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Boehringer Ingelheim

Boehringer Ingelheim Market Analysis and Financial Projection

Last updated: February 11, 2026

Boehringer Ingelheim: Market Position, Strengths & Strategic Insights

Boehringer Ingelheim (BI) occupies a significant niche in the pharmaceutical sector, primarily focusing on respiratory, oncology, cardiovascular, and metabolic diseases. The company generated €23.4 billion in 2022 revenue, ranking among the top 15 pharmaceutical firms globally. Its presence spans over 150 markets, with substantial R&D investment constituting approximately 19% of total revenue in 2022, equating to €4.4 billion.

---

What Is Boehringer Ingelheim’s Market Position?

Market Ranking and Revenue Breakdown

Segment	Revenue (2022)	Share of Total Revenue	Notable Products/Focus Areas
Respiratory	€10.8 billion	46%	Spiriva (tiotropium), Spiolto (tiotropium/olodaterol)
Oncology	€2.8 billion	12%	Tyvyt (sintilimab), Boehringer’s expanding checkpoint inhibitors
Cardiovascular & Metabolism	€3.0 billion	13%	Pradaxa (dabigatran), Jardiance (empagliflozin)
Neuroscience	€1.9 billion	8%	N/A
Others	€4.9 billion	21%	Vaccines, animal health products

Global Presence

• Top markets: Germany, U.S., China, Japan, France
• R&D centers: Over 20 worldwide
• Partnerships: Strategic alliances with Roche, Lilly, and others

Boehringer Ingelheim ranks within the top 15 in global pharma revenue, with a strategic focus on respiratory and oncology segments. Its growth is driven by innovative products and its presence in emerging markets.

What Are the Key Strengths of Boehringer Ingelheim?

Robust R&D Infrastructure

BI invests heavily in R&D, with a focus on transformative therapies. The company has over 12,000 employees in R&D and holds approximately 2,200 active patents. Its pipeline includes over 170 clinical candidates across varied therapeutic areas, emphasizing biologics and immunotherapies.

Strong Portfolio in Respiratory and Oncology

• Respiratory: Spiriva remains a leading long-acting muscarinic antagonist (LAMA) for COPD.
• Oncology: Tyvyt (sintilimab), approved in China, signifies BI’s expanding immunotherapy capabilities.

Strategic Collaborations

Partnerships enable access to novel technologies, particularly in immuno-oncology and rare diseases. An example is the collaboration with Innovent for drug development in China.

Operational Flexibility and Focus

BI maintains a lean organization with a narrow product focus, allowing rapid decision-making. It chooses to prioritize core areas where it has competitive strength, particularly respiratory and oncology therapeutics.

What Are the Strategic Insights for BIo and Investors?

Market Trends

• Growing prevalence of respiratory diseases, especially COPD and asthma, sustain demand for Spiriva and comparable drugs.
• The global oncology market surpasses $220 billion, projected to grow at a CAGR of 7.6% through 2028, increasing opportunities for BI’s immunotherapy portfolio.
• Shift toward biologics and targeted therapies creates opportunities for BI’s pipeline.

Emerging Markets

• China and parts of Asia show promising growth, driven by increasing healthcare infrastructure and rising disease prevalence.
• Investments aligned with local regulatory reforms (e.g., China’s Accelerated Approval pathway) support faster product launches.

Pipeline Development and Patent Expirations

• Key patents for blockbuster drugs like Pradaxa and Spiriva are approaching expiration (2030–2035), prompting BI to diversify revenue sources.
• Focus on biologics and immunotherapies aims to replace declining revenue streams.

Competitive Risks

• Patent expiries risk revenue declines from core drugs.
• Rising R&D costs and regulatory challenges persist.
• Intense competition in respiratory and oncology markets from Pfizer, GSK, Novartis, and Merck.

Strategic Moves

• Acquisition of late-stage assets in immuno-oncology.
• Expansion into neuroscience through internal R&D and collaborations.
• Digital transformation initiatives for R&D productivity and supply chain efficiencies.

Competitive Landscape Overview

Competitors	Key Strengths	Market Focus	Notable Products
Pfizer	Large R&D, global reach	Oncology, vaccines	Ibrance, Prevnar
GSK	Respiratory and vaccines	Respiratory, vaccines	Advair, Shingrix
Novartis	Innovative biologics	Oncology, ophthalmology	Cosentyx, Lucentis
Merck	Oncology, vaccines	Oncology, infectious diseases	Keytruda, Gardasil

Boehringer Ingelheim competes through a focused portfolio with deep activity in respiratory and immuno-oncology areas, primarily targeting unmet needs within chronic disease management and rare cancers.

---

Key Takeaways

• Boehringer Ingelheim holds a prominent position in respiratory and oncology markets, with revenues exceeding €23 billion in 2022.
• Its strengths include robust R&D, strategic collaborations, a focus on biologics, and geographic expansion into emerging markets.
• Patent expirations pose risks, balanced by pipeline growth and diversification toward biologics and immunotherapies.
• Competition is intense, with key rivals like Pfizer, GSK, and Novartis maintaining significant market share across major segments.
• Strategic investments in R&D and partnerships aim to sustain growth amid patent cliffs and evolving market dynamics.

---

5 FAQs

1. How does Boehringer Ingelheim’s R&D expenditure compare to its competitors?
BI invests approximately 19% of its revenue into R&D (€4.4 billion), comparable to industry leaders like Pfizer and Novartis, which typically invest 13–20%. This high investment underscores its focus on innovation.

2. Which markets are critical for BI’s growth strategy?
Germany, U.S., China, and Japan remain core markets. China offers rapid growth opportunities due to healthcare reforms and a large patient base, especially in oncology.

3. Will patent expiries significantly impact BI’s revenue?
Yes. Key patents for Garbing drugs like Spiriva and Pradaxa are set to expire between 2030-2035, risking revenue decline. Continual pipeline development aims to mitigate this.

4. In what areas is BI expanding its portfolio?
Biologics, immunotherapy, and neuroscience. The company expanded its oncology pipeline with sintilimab, especially in China.

5. What are the main risks facing Boehringer Ingelheim?
Patent expiration impact, high R&D costs, regulatory hurdles, and aggressive competition from established pharmaceutical giants.

---

Citations

1. Boehringer Ingelheim Annual Report 2022.
2. IQVIA, "World Preview 2022: Healthcare and Pharmaceutical Trends," 2022.
3. Evaluate Pharma, "Global Oncology Market," 2022.
4. Pharma intelligence, "Patent Expiry Calendar," 2022.
5. GlobalData, "Emerging Markets Opportunities," 2022.